Loading
A phase 1 trial of Gintemetostat run by K36 Therapeutics, Inc., now recruiting.
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma is a phase 1 interventional study registered as NCT05651932 by K36 Therapeutics, Inc., with 165 participants planned, started 2023-02-22. Conditions recorded: Multiple Myeloma, Myeloma and Myeloma Multiple. Interventions recorded: Cohort A1 & A2: KTX-1001, Cohort B1 & B2: KTX-1001+Mezigdomide, Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®) and Cohort D: KTX-1001+ pomalidomide (Pomalyst, Imnovid).
Shares K36 Therapeutics and the tag pipeline.
Shares K36 Therapeutics and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/